CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
CMAC Open Day 2017 - Registration is Open
Please join us on 23-24 March for the CMAC Open Day 2017.... more
DIT and SDI visit CMAC
CEO of Department for International Trade (Life Sciences), and his team visited CMAC with colleagues from Scottish Development International (SDI).... more
CMAC at the 4th Winter Process Chemistry Conference
Hosted by 'EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC)' at The University of Strathclyde, the 4th Winter Process Conference was held in TIC, Glasgow from 12-14 Dec 2017.... more